Immune Thrombocytopenia Treatment Market
Apr 30, 2024
X4 Pharmaceuticals’ XOLREMDI FDA Approval; ONO to Acquire Deciphera Pharmaceuticals; Johnson & Johnson’s SIRTURO CHMP Approval; BeiGene’s Tislelizumab EC Approval; Sanofi’s Rilzabrutinib LUNA 3 Phase III Trial
FDA Greenlights XOLREMDI Capsules from X4 Pharmaceuticals for WHIM Syndrome Treatment X4 Pharmaceuticals has declared that the FDA has granted approval for XOLREMDI™ (mavorixafor) capsules to be utilized in individuals aged 12 and above who have WHIM syndrome (characterized by warts, hypogammaglobulinemia, infec...
Read More...
Jan 22, 2021
Thrombocytopenia Drugs Market: What Newer Agents Are Expected To Enter The Market?
The launch of a novel drug in the market is not less than a celebration in the pharmaceutical and healthcare market; however, it also brings the real challenge of sustenance in the market. Similar is the picture of the Thrombocytopenia Drugs Market. Thrombocytopenia pipeline possesses potential drugs in mid-stage d...
Read More...
May 25, 2020
R&D and Upcoming therapies Paving the Way for a Potential and Better Cure for Immune Thrombocytopenia
The Immune Thrombocytopenia market size in the 7MM was estimated to be approximately USD 2,527.72 million in 2017. The US accounts for the largest ITP Market size. A disorder that results in an isolated low platelet count, Immune thrombocytopenia (ITP), is an autoimmune disorder that results in convincing body...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
